Drug intelligence / Profile preview

iPCE-120

Development stage: Preclinical
Lead developer: Cello Therapeutics
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics

Overview

iPCE-120 is a therapeutic vaccine under development by Cello Therapeutics, Inc. for the treatment of solid tumors. As a therapeutic vaccine, it is designed to stimulate the immune system to recognize and attack cancer cells in patients with neoplasms (solid tumors). The specific mechanism of action, molecular targets, and detailed composition have not been publicly disclosed as of June 2025. The drug remains in preclinical development and has not yet entered human clinical trials[6].

Beyond the preview

Go deeper on iPCE-120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iPCE-120.

Explore the full profile